Vaccination With Lethally Irradiated Autologous Myeloblasts With Granulocyte Macrophage-Colony Stimulating Factor Secreting K562 Cells (GM-K562) in Patients With Advanced MDS or AML After Allogeneic Hematopoietic Stem Cell Transplantation.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GM-CSF-transduced tumour cell vaccine (Primary)
Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use

Most Recent Events

16 Sep 2020 Biomarkers information updated
19 Dec 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
22 Jun 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight